NCT00562289View on ClinicalTrials.gov

Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence

PHASE3CompletedINTERVENTIONAL

Enrollment

664

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Ischemic StrokePatent Foramen OvaleAtrial Septal AneurysmMigraine

Interventions

DRUG

aspirin

during the follow up

DRUG

Antivitamins K or rivaroxaban or dabigatran or apixaban

during the follow up

DEVICE

Devices for PFO closure

endovascular treatment no longer than 21 days after the random.

Trial Locations (1)

Unknown

Hôpital Saint-Anne, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00562289 - Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence | Biotech Hunter | Biotech Hunter